Results 241 to 250 of about 141,528 (311)
Co-expression of MARCKS and GSDMD pathway genes in tuberculous meningitis: a multi-omics analysis of blood-brain barrier disruption. [PDF]
Luan M, Chen X, Lu Y.
europepmc +1 more source
Intelligent design of artificial biocatalyst for biomedical diseases
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang +3 more
wiley +1 more source
Exendin-4 protects brain endothelial cell damage against hyperammonemic condition. [PDF]
Ahn SY, Jo D, Choi SY, Song J.
europepmc +1 more source
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng +14 more
wiley +1 more source
Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis. [PDF]
Xu W, Xu T, Long H, Jiang Q, Liao W.
europepmc +1 more source
Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy
Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao +8 more
wiley +1 more source
Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis. [PDF]
Ji W +5 more
europepmc +1 more source
Abstract Background Blood–brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear. Objectives The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to ...
Jonas Folke +15 more
wiley +1 more source
Nanoparticles that target nonamyloid and nontau pathways in Alzheimer's disease. [PDF]
Alavian F, Hajimohammadi A.
europepmc +1 more source

